Louisiana State Employees Retirement System Buys New Position in Thermo Fisher Scientific Inc. $TMO

Louisiana State Employees Retirement System purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, Holdings Channel.com reports. The fund purchased 19,100 shares of the medical research company’s stock, valued at approximately $9,388,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Assetmark Inc. grew its position in Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after buying an additional 7,023 shares during the last quarter. Mackenzie Financial Corp grew its holdings in shares of Thermo Fisher Scientific by 29.4% in the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after acquiring an additional 62,790 shares during the last quarter. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $7,505,000. Fisher Asset Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.2% during the third quarter. Fisher Asset Management LLC now owns 2,721,101 shares of the medical research company’s stock valued at $1,319,789,000 after purchasing an additional 31,298 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its stake in Thermo Fisher Scientific by 30.9% in the 3rd quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock worth $6,924,000 after purchasing an additional 3,369 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Trading Up 2.8%

Thermo Fisher Scientific stock opened at $506.19 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $401.45 and a 12 month high of $643.99. The company’s fifty day simple moving average is $474.44 and its 200-day simple moving average is $520.23. The stock has a market cap of $188.11 billion, a P/E ratio of 27.83, a P/E/G ratio of 2.18 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the firm earned $5.15 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a report on Thursday, May 14th. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Finally, Piper Sandler started coverage on Thermo Fisher Scientific in a report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $608.95.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher is showcasing new AI-enabled, end-to-end biopharma tools at the BIO International Convention, including Orbitrap mass spectrometry upgrades, AI software, and integrated lab solutions, reinforcing its position as a full-service partner in drug development. Is Thermo Fisher (TMO) Quietly Redefining Its Edge With AI-Enabled, End-to-End Biopharma Tools?
• Positive Sentiment: Recent commentary highlighted support from Thermo Fisher’s long-range growth targets, Clario acquisition integration, and fresh analyst optimism, all of which can help lift the stock when investors are looking for visibility and execution upside. Thermo Fisher gains as investors weigh growth targets, Clario integration, and fresh analyst support
• Neutral Sentiment: Multiple industry pieces continued to position Thermo Fisher as a key player in fast-growing life sciences and lab services markets, which supports the broader investment thesis but is not a direct near-term catalyst. Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035
• Neutral Sentiment: Thermo Fisher’s Q1 earnings comparison article does not point to a new operational surprise, but it reinforces that the company has been delivering solid results relative to peers. Q1 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.